Abstract
Summary:
Our objective was to evaluate, probably for the first time, the impact of CD34 subsets on engraftment kinetics in allogeneic PBSC transplantation (PBSCT). PBSC graft components were analyzed in 62 cases for the absolute count/kg of total CD34+ and the following subsets: DR− and +, CD71+/−, CD38+/−, CD33+/− and CD61+/−. Time to ANC >0.5 and >1 × 109/l and platelets >20 and >50 × 109/l was reported. The median value for each parameter was used to discriminate rapid from slow engraftment. Four parameters showed significant predictive power of early neutrophil engraftment, namely CD34+/DR− (P=0.002), CD34+/38− (P=0.02), CD34+/CD61− (P=0.04) and total CD34+ cell dose (P=0.04). Four parameters showed significant predictive power of early platelet engraftment, namely CD34+/CD61+ (P=0.02), CD34+/CD38− and total CD34+ cell dose (P=0.04) and CD34+/CD71− (P=0.05). Comparing patients who received >to those who received < the threshold dose(s), only CD34+/CD38− lost its significance for neutrophil engraftment; and only CD34+/CD61+ retained its significance for platelet engraftment (P=0.03); furthermore, the former group required significantly fewer platelet transfusions (P=0.018). We concluded that in allogeneic PBSCT, the best predictor of early neutrophil engraftment is the absolute CD34+/DR− and for early platelet engraftment is the absolute CD34+/CD61+ cell dose.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andrews RG, Briddell RA, Hill R et al. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF, MGDF decreases the duration and severity of neutropenia. Stem Cells 1999; 17: 210–218.
Siena S, Schavo R, Pedrazzoli P, Carlo-Stella C . Therapeutic relevance of CD34 cell dose and blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–1377.
Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear allografts affects engraftment kinetics and development of extensive chronic graft versus host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221–3227.
Belvedere O, Feruglio C, Malangone W et al. Increased blood volume and CD34+/CD38− progenitor cell recovery using a novel umbilical cord blood collection system. Stem Cells 2000; 18: 245–251.
Cutler C, Giri S, Jeyapalan S . Incidence of acute and chronic graft versus host disease after allogeneic peripheral blood stem cell and bone marrow transplantation: a meta-analysis. Blood 2000; 96: 205a (Abstract).
Mahmoud HK, Fahmy OA, Kamel A et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355–358.
Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213–226.
Cutler C, Antin JH . Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells 2001; 19: 108–117.
Schmitz N, Bacigalupo A, Hasenclever D . Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of randomised multicentre trial of European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995–1002.
Blaise D, Kuentz M, Bontrop RE, Fortanier C . Randomized trial of bone marrow versus lenogastrim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 534–546.
Powles R, Mehta J, Kulkarni S . Allogeneic and bone marrow stem cell transplantation in hematological malignant diseases: a randomised trial. Lancet 2000; 335: 1231–1237.
Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoieic cells for allogeneic transplantation. Blood 2000; 95: 3702–3709.
Pratt G, Rawstron AC, English AE et al. Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 2001; 114: 937–943.
Miflin G, Russell NH, Hutchinson RM . Allogeneic blood stem cell transplantation for haematological malignancies – an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997; 19: 9–13.
Shpall EJ, Champlin R, Glaspy JA . Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92.
Johnsen HE, Knudsen LM, Shiodt I et al. Delayed platelet recovery is predicted by CD34+ subset enumeration and not by CD34+ quantification in most patients autotransplanted. The International Society for Hematotherapy and Graft Engineering (ISHAGE), Oslo, Norway, May 28–June 1 (Abstract).
Mavroudis DA, Read EJ, Cottler-Fox M et al. CD34+ cell dose predicts survival, post transplant morbidity and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–3229.
Ilhan O, Arslan O, Arat M . The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. Transfus Sci 1999; 20: 69–71.
Banett D, Granger V, Kraan J et al. Reduction of intra- and inter laboratory variation in CD34+ stem cell enumeration using stable test material, standard protocol and targeted training. Br J Haematol 2000; 108: 784–792.
Gonzalez-Requejo A, Madero L, Diaz MA et al. Progenitor cell subset and engraftment kinetics in children undergoing autologous peripheral blood stem cell transplantation. Br J Haematol 1998; 101: 104–110.
Pecora AL, Preti RA, Gleim GW et al. CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 1998; 16: 2093–2104.
Millar BC, Millar JL, Shepherd V et al. The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. BMT 1998; 22: 469–475.
Vigorito AC, Azevedo WM, Marques JF . A randomized prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145–1151.
Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA identical relatives in patients with hematologic cancers. N Engl J Med 2001; 244: 175–181.
Azevedo WM, Aranha FJP, Gouvea AC et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies. Bone Marrow Transplat 1995; 16: 647–653.
Przepiorka D, Smith TL, Folloder J . Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465–1470.
Kubel M, Leiblein S, Ponisch W . Comparison of HLA-identical transplantation of unselected blood stem cells (PBSCT) and bone marrow (BMT) from related donors in patients with hematologic malignancy: a single center report. Bone Marrow Transplant 1998; 22 (Suppl. 2): S27 (Abstract).
Couban S, Simpson DR, Barnett MJ et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525–1531.
Flowers MED, Parker PM, Johnston LJ et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long term follow up of a randomized trial. Blood 2002; 100: 415–419.
Elmaagacli A, Beelen DW, Opalka B . The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999; 94: 384–389.
Bensinger WI, Martin P, Clift R . A prospective randomized trial of peripheral blood stem cells (PBSC) or bone marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies. Blood 1999; 94 (Suppl 1): 10a (Abstract).
Diez-Campelo M, Perez-Sim JA, Martino A et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Hematol J 2003; 4 (Suppl 2): 0460 (Abstract).
Haas R, Witt B, Mohle R et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754–3761.
Salazar R, Sola C, Maroto P . Factors affecting CD34+ cell mobilization with cyclophosphamide and G-CSF and hematopoietic recovery after high-dose chemotherapy and stem cell support in solid tumor patients. Proc Am Soc Clin Oncol 1996; 17: 95a (Abstract).
Beguin O, Baudoux E, Sautois B . Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells. Transfusion 1998; 38: 199–208.
Stewart DA, Guo D, Luider J et al. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cell as well as the total CD34+ cell dose. Bone Marrow Transplant 2000; 25: 435–440.
Dazzi C, Cariello A, Rosti G et al. Relationships between total CD34+ cells reinfused, CD34+ subsets and engraftment kinetics in breast cancer patients. Hematologica 2000; 85: 396–402.
Baech J, Johnsen HE . Concise review: technical aspects and clinical impact of hematopoietic progenitor subset quantification. Stem Cells 2000; 18: 76–86.
Drecksen MW, Gerritsen WR, Rodenhuis S et al. Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 1995; 11: 3313–3319.
Drecksen MW, Rodenhuis S, Dirkson MKA et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995; 13: 1922–1932.
Verfaillie CM, Ploemacher R, Di Persio J et al. ISHAGE scientific committee report: assays to determine hematopoietic stem cell content in blood or marrow grafts. Cytotherapy 1999; 1: 41–49.
Watts MJ, Sullivan AM, Jamieson E et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–546.
Van-der Wall E, Richel DJ, Holtkamp MJ et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood stem cell transplantation: effect of graft size. Ann Oncol 1994; 5: 795–802.
Bensinger WI, Appelbaum FR, Rowley S et al. Factors influencing collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547–2555.
Glaspy J, Lu ZJ, Wheeler C . Economic rationale for infusing optimal numbers of CD34+ cells in peripheral blood progenitor cell transplants. Blood 1997; 90 (Suppl. 1): 370a (Abstract).
Kiss JE, Rybka WB, Winkelsein A et al. Relationships of CD34+ cell dose to early and late hematopoiesis following autologous peripheral-blood stem-cell transplantation. Bone Marrow Transplant 1997; 19: 303–310.
Ketterer N, Salles G, Raba M et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155.
Migliaccio AR, Adamson JW, Stevens CE et al. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 2000; 96: 2717–2722.
Von Drygalski A, Xu G, Constantinescu D et al. The frequency and proliferative potential of megakaryocytic colony-forming cells (Meg-CFC) in cord blood, cytokine mobilized peripheral blood and bone marrow, their correlation with total CFC numbers: implications for the quantitation of Meg-CFC to predict platelet engraftment following cord blood transplantation. BMT 2000; 25: 1029–1034.
Sola C, Maroto P, Salazar R . High dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) autologous transplantation: influence of the number of infused CD34+ cells in hematopoietic recovery and support measures required. Oncol 1996; 15: 538 (Abstract).
Henon PH, Sovalat H, Bourderont D . Importance of CD34+ cell subsets in autologous PBSC transplantation, the mulhouse experience using CD34+ CD38− cells as predictive tool for hematopoietic engraftment. J Biol Regul Homeost 2001; 15: 62–67.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kamel, A., El-Sharkawy, N., Mahmoud, H. et al. Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 35, 129–136 (2005). https://doi.org/10.1038/sj.bmt.1704755
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704755
Keywords
This article is cited by
-
Nomogram for Predicting Early Mortality after Umbilical Cord Blood Transplantation in Children with Inborn Errors of Immunity
Journal of Clinical Immunology (2023)
-
Allogeneic transplantation of peripheral blood stem cell grafts results in a massive decrease of primitive hematopoietic progenitor frequencies in reconstituted bone marrows
Bone Marrow Transplantation (2020)
-
Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients
Wiener klinische Wochenschrift (2017)
-
Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources
Bone Marrow Transplantation (2016)
-
Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization
Stem Cell Research & Therapy (2013)